Table 1: Characteristics of the present cohort (cut-off, August 31, 2017).

Case #Age, at diagnosisPrimary resectionFirst diagnosis of bone metastasisReceptor statusAny metastasis before AFTV treatmentTreatments after primary resection and before diagnosis of PDBest response of bone metastasis after AFTV treatmentOutcome by Feb & Aug 2017OS after the first diagnosis of bone metastasis (months)

1592004/4/212004/2/9HER2(−), ER(++), PgR(++)Multiple bones (more than 30), liverChemo, AFTV 4 cr, chemo, RT (30 Gy), aromatase inhibSD for 5 monthsDead
2008/02/21
49

2742001/2/22003/1/15HER2(−), ER(−), PgR(−)Rib, neck, sacrumRib resec, RT (30 Gy), chemo, AFTV 2 crPDDead
2009/01/15
73

3501999/5/102005/7/11Not testedBrain, pelvis, sacrumBrain operation, RT to brain (35 Gy), AFTV 1 cr, aromatase inhib, RT to sacrum (30 Gy)SD for 12 monthsDead
2008/05/07
34

4561999/6/182003/3/6HER2(+), ER(+), PgR(−)Lymph node (19/20), sternum, lung (multiple), liver, brain (multiple), pelvisRT (50 Gy), resec, aromatase inhib, chemo, resect, RT (35 Gy to pelvis, 35 Gy to brain), AFTV 1 cr + chemoSD for 13 monthsDead
2007/07/28
54

5522003/7/82004/11/10HER2(−), ER(−), PgR(−)Lymph node, bone (multiple), lungRT (30 + 30 Gy), chemo, AFTV 4 cr + RT (Th6 30 Gy, Th11 30 Gy)PDDead
2009/8/30
58

6522006/8/72006/7/31HER2(−), ER(−), PgR(−)Vertebra Th7AFTV 1 cr, RT (36 Gy), chemo, aromatase inhib (misprescription), zoledronateCR for 50 months or moreOngoing128+

7422004/3/52006/6/24HER2(−), ER(+), PgR(+)Liver, lung, chest wall, lymph nodes, pelvisRT (30 Gy), chemo, resec, chemo + aromatase inhib, RT (35 Gy), zoledronate, AFTV 3 cr, chemoPDDead
2007/11/18
17

8452001/3/92007/3/1HER2(−), ER(−), PgR(++)Bone (multiple)Resec, aromatase inhib, zoledronate, AFTV 3 cr, RT (30 Gy)PDDead
2012/11/16
70

9712004/3/232006/12/15HER2(−), ER(+), PgR(−)Bone (multiple), skin, lymph node, chest wallChemo, aromatase inhib, AFTV 1 cr, chemoPDDead
2008/7/28
20

10622007/6/162010/1/28HER2(−), ER(−), PgR(−)Lymph node (2/7) [bone (multiple) after AFTV]Chemo, AFTV 1 cr, chemo, aromatase inhib (misprescription), zoledronatePDDead
2010/9/20
8

11462004/3/102007/5/14HER2(−), ER(++), PgR(++)Lymph node, lung, rib (2 sites), pedicle of thoracic vertebraAFTV 4 cr, zoledronate, aromatase inhib, chemoSD for 55 monthsOngoing, bearing bone-meta118+

12751992/10/72007/5/25HER2(−), ER(−), PgR(−)RibChemo, resec, AFTV 1 crPDDead
2008/5/23
12

13641998/5/122006/6/14HER2(+++), ER(+++), PgR(+++)Chest wall, bone (multiple)Resec, chemo, aromatase inhib, RT (28 Gy, 30 Gy, 30 Gy), zoledronateSD for 25 monthsOngoing130+

14611999/6/282004/12/16HER2(+++), ER(+), PgR(−)Lung, vertebra Th10Resec, AFTV 1 cr, TAE, chemo, zoledronatePDDead
2015/4/4
125

15392007/11/92008/12/9HER2(−), ER(−), PgR(+++)Lymph node (23/24), pelvisChemo, AFTV 1 cr, zoledronate, RT (30 Gy)PDDead
2013/11/12
60

16522000/6/302007/9/27HER2(+), ER(−), PgR(++)Lymph node (1/26), bone (multiple)RT (60 Gy), AFTV 1 cr, zoledronateSD for more than 80 monthsOngoing114+

17502009/3/182015/6/18HER2(−), ER(+), PgR(−)SternumAFTV 2 cr, aromatase inhib, RT (36 Gy), zoledronate, anti-PD-1 AbCR for 18 months or moreOngoing26+

18562011/3/112013/8/9HER2(++), ER(+++), PgR(+++)Vertebra L5, lymph node (1/5)AFTV 2 cr, RT (30 Gy to vertebra + 50 Gy to axilla), chemo, zoledronate, tumorectomy of chest wall meta, aromatase inhib, RT (40 Gy) to lymph nodeBone local control for 22 months, but clinically PDDead
2016/10/17
39

19642004/12/22013/9/4HER2(+++), ER(−), PgR(−)Lymph node (4/5), vertebrae L3, L5Chemo, G-CSF, RT (60 Gy to neck lymph node), trastuzumab, AFTV 1 cr, RT (36 Gy) to vertebra L3, vertebra L5, zoledronate, resect (chest wall), RT (60 Gy) to chest wall, RT (60 Gy) to lymph nodeCR for 11 months, then PDOngoing42+

20462000/7/142013/10/20HER2(−), ER(+), PgR(++)Sternum, lymph nodeToremifene, RT (60 Gy), AFTV 2 cr, zoledronate, anti-PD-1 AbCR for 17 months, then PDOngoing40+

AFTV, autologous formalin-fixed tumor vaccine; chemo, chemotherapy; CR, complete response; cr, course; inhib, inhibitor; meta, metastasis; OS, overall survival; PD, progressive disease; resec, resection; RT, radiation therapy; SD, stable disease.